Immunome Inc (IMNM)

$22.78 +0.62 (2.80%)
Market Cap 2.51B
Revenue (ttm) 6.94M
Net Income (ttm) -212.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,060.37%
Debt to Equity Ratio 0.00
Volume 781,400
Avg Vol 1,482,432
Day's Range N/A - N/A
Shares Out 113.25M
Stochastic %K 37%
Beta 2.07
Analysts Strong Sell
Price Target $35.77

Company Profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 939 7410
Address:
18702 North Creek Parkway, Suite 100, Bothell, United States
EZ_Money11
EZ_Money11 Jul. 20 at 11:36 AM
$IMNM 🗞️
0 · Reply
JFais
JFais Jul. 14 at 9:17 PM
$PBLS - strong price action since IPO, marching to new highs (initial data in desmoid looks better than $IMNM and $SWTX + quite a few expansion opportunities on deck) More of this is good for $XBI (vs "science projects" coming to market & blowing up, burning investors like the 2021 bubble)
0 · Reply
Davidendz
Davidendz Jul. 14 at 6:16 PM
$BVAXF Temp halt on $BIOV.CSE $BVAXF = paperwork after nabbing DPX platform in '24. MVP-S data popping, Sona collab, Tartaglia firepower! Platform ready to roll like $IBRX $IMNM.
1 · Reply
Davidendz
Davidendz Jul. 14 at 6:15 PM
$BVAXF Halt on $BIOV.CSE sucks but DPX deal closed 2024, they're building a real platform. Check $IMNM $STOK for similar vibes. Loading when it frees up.
0 · Reply
Davidendz
Davidendz Jul. 14 at 6:15 PM
$BVAXF Frustrating halt on $BIOV $BVAXF but DPX platform fully acquired 2024, smart move for broad applications. Positive trials, Tartaglia hire, partnerships stacking up. Long-term value play like other immuno platforms $IMNM $IMCR. Patient holders win when filings clear!
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 13 at 1:18 PM
Radiopharm Theranostics ($RADX) Jumps as Nuclear-Medicine Interest Builds $LNTH $IMNM $PYXS Source: Kalkine https://kalkine.com.au/news/healthcare/radiopharm-theranostics-asxrad-jumps-as-nuclear-medicine-interest-builds
0 · Reply
FlyontheCEOSwall
FlyontheCEOSwall Jul. 10 at 7:45 PM
$IMNM he can sell it anytime he wants to bears so when he does it will be substantial
0 · Reply
fda_tracker
fda_tracker Jul. 9 at 6:51 PM
$IMNM New PDUFA Date 2027-04-28 IMMUNOME, INC. Link: https://www.businesswire.com/news/home/20260708283482/en/Immunome-Announces-U.S.-FDA-Acceptance-of-New-Drug-Application-for-Varegacestat-for-the-Treatment-of-Adults-with-Desmoid-Tumors Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
Merlintrader
Merlintrader Jul. 9 at 6:00 AM
$IMNM Immunome Deep Dive: Varegacestat Enters FDA Review and Turns $IMNM Into a Cleaner Regulatory-Catalyst Story https://www.merlintrader.com/immunome-imnm-varegacestat-fda-pdufa-2027/
0 · Reply
Jeff9905
Jeff9905 Jul. 8 at 12:15 PM
$IMNM great news. Why is it down?
1 · Reply
Latest News on IMNM
Immunome announces first patient dosed in Phase 1 IM-3050 trial

2026-07-20T11:36:01.000Z - 1 day ago

Immunome announces first patient dosed in Phase 1 IM-3050 trial

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Jul 20, 2026, 7:30 AM EDT - 1 day ago

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA

2026-07-08T11:35:15.000Z - 13 days ago

Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Jul 8, 2026, 7:30 AM EDT - 13 days ago

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 7, 2026, 4:02 PM EDT - 14 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome announces first patient dosed in Phase 1 trial of IM-1617

2026-06-11T11:43:23.000Z - 5 weeks ago

Immunome announces first patient dosed in Phase 1 trial of IM-1617

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Jun 11, 2026, 7:30 AM EDT - 5 weeks ago

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Immunome Transcript: AGM 2026

Jun 9, 2026, 12:00 PM EDT - 6 weeks ago

Immunome Transcript: AGM 2026

Immunome Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 6 weeks ago

Immunome Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Immunome announces Ringside trial met primary, secondary endpoints

2026-05-31T13:20:05.000Z - 7 weeks ago

Immunome announces Ringside trial met primary, secondary endpoints

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

May 30, 2026, 8:00 AM EDT - 7 weeks ago

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

Immunome Slides: Investor presentation

May 29, 2026, 7:00 AM EDT - 7 weeks ago

Immunome Slides: Investor presentation

Immunome price target raised to $37 from $36 at Truist

2026-05-28T13:50:37.000Z - 7 weeks ago

Immunome price target raised to $37 from $36 at Truist

Immunome initiated with an Overweight at Barclays

2026-05-28T09:25:08.000Z - 7 weeks ago

Immunome initiated with an Overweight at Barclays

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026, 8:00 AM EDT - 7 weeks ago

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Immunome price target lowered to $33 from $37 at Leerink

2026-05-15T10:26:52.000Z - 2 months ago

Immunome price target lowered to $33 from $37 at Leerink

Immunome reports Q1 EPS (48c), consensus (54c)

2026-05-12T22:13:25.000Z - 2 months ago

Immunome reports Q1 EPS (48c), consensus (54c)

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 4:02 PM EDT - 2 months ago

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 2 months ago

Immunome Earnings release: Q1 2026

Immunome Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 2 months ago

Immunome Quarterly report: Q1 2026

Immunome announces submission of NDA for varegacestat in desmoid tumors

2026-04-29T12:33:14.000Z - 2 months ago

Immunome announces submission of NDA for varegacestat in desmoid tumors

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Apr 29, 2026, 7:30 AM EDT - 2 months ago

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Immunome Proxy statement: Proxy filing

Immunome Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Immunome Proxy statement: Proxy filing

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Apr 21, 2026, 10:30 AM EDT - 3 months ago

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Apr 14, 2026, 4:54 PM EDT - 3 months ago

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead

Immunome Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:00 PM EDT - 4 months ago

Immunome Transcript: Leerink Global Healthcare Conference 2026

Immunome price target lowered to $30 from $32 at Lake Street

2026-03-05T13:43:42.000Z - 4 months ago

Immunome price target lowered to $30 from $32 at Lake Street

Immunome price target raised to $36 from $33 at Craig-Hallum

2026-03-04T14:16:41.000Z - 4 months ago

Immunome price target raised to $36 from $33 at Craig-Hallum

Immunome price target lowered to $30 from $33 at Stephens

2026-03-04T12:17:08.000Z - 4 months ago

Immunome price target lowered to $30 from $33 at Stephens

Immunome price target raised to $39 from $35 at JPMorgan

2026-03-04T11:37:36.000Z - 4 months ago

Immunome price target raised to $39 from $35 at JPMorgan

Immunome reports FY25 EPS ($2.43), consensus ($2.21)

2026-03-03T21:15:38.000Z - 5 months ago

Immunome reports FY25 EPS ($2.43), consensus ($2.21)

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 4:02 PM EST - 5 months ago

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Immunome Annual report: Q4 2025

Mar 3, 2026, 3:00 PM EST - 5 months ago

Immunome Annual report: Q4 2025

Immunome Earnings release: Q4 2025

Mar 3, 2026, 3:00 PM EST - 5 months ago

Immunome Earnings release: Q4 2025

Immunome Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:50 AM EST - 5 months ago

Immunome Transcript: TD Cowen 46th Annual Health Care Conference

Immunome Slides: Corporate presentation

Mar 3, 2026, 7:00 AM EST - 5 months ago

Immunome Slides: Corporate presentation

Immunome to Present at Upcoming Investor Conferences

Feb 23, 2026, 8:00 AM EST - 5 months ago

Immunome to Present at Upcoming Investor Conferences

Immunome initiated with a Buy at H.C. Wainwright

2026-02-12T11:11:35.000Z - 5 months ago

Immunome initiated with a Buy at H.C. Wainwright

Immunome Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 9:00 AM EST - 5 months ago

Immunome Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 8:00 AM EST - 5 months ago

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Immunome Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 1:30 PM EST - 6 months ago

Immunome Transcript: 44th Annual J.P. Morgan Healthcare Conference

Immunome Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 1:30 PM EST - 6 months ago

Immunome Slides: 44th Annual J.P. Morgan Healthcare Conference

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 7 months ago

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Immunome falls -7.2%

2025-12-17T15:06:41.000Z - 7 months ago

Immunome falls -7.2%

Immunome 18.625M share Spot Secondary priced at $21.50

2025-12-17T01:20:19.000Z - 7 months ago

Immunome 18.625M share Spot Secondary priced at $21.50

Immunome Announces Pricing of Public Offering of Common Stock

Dec 16, 2025, 8:16 PM EST - 7 months ago

Immunome Announces Pricing of Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 7 months ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome Transcript: Study Result

Dec 15, 2025, 8:30 AM EST - 7 months ago

Immunome Transcript: Study Result

Immunome Press release: Study Result

Dec 15, 2025, 8:30 AM EST - 7 months ago

Immunome Press release: Study Result

Immunome Slides: Study Result

Dec 15, 2025, 8:30 AM EST - 7 months ago

Immunome Slides: Study Result

Immunome's experimental drug meets main goal in late-stage study

Dec 15, 2025, 7:16 AM EST - 7 months ago

Immunome's experimental drug meets main goal in late-stage study

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 15, 2025, 7:00 AM EST - 7 months ago

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome Slides: Corporate presentation

Dec 15, 2025, 7:00 AM EST - 7 months ago

Immunome Slides: Corporate presentation

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 14, 2025, 4:00 PM EST - 7 months ago

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 9:10 AM EST - 8 months ago

Immunome Transcript: Evercore ISI 8th Annual HealthCONx Conference

Immunome Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 9:00 AM EST - 8 months ago

Immunome Transcript: Piper Sandler 37th Annual Healthcare Conference

Immunome Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 8:30 AM EST - 9 months ago

Immunome Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Immunome Slides: Corporate Presentation

Nov 10, 2025, 6:00 PM EST - 9 months ago

Immunome Slides: Corporate Presentation

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 9 months ago

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Immunome Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 9 months ago

Immunome Earnings release: Q3 2025

Immunome Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 9 months ago

Immunome Quarterly report: Q3 2025

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Oct 31, 2025, 11:51 AM EDT - 9 months ago

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Oct 23, 2025, 12:00 PM EDT - 9 months ago

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Infinimmune Announces Research Collaboration with Immunome

Sep 18, 2025, 8:00 AM EDT - 10 months ago

Infinimmune Announces Research Collaboration with Immunome

Immunome Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:00 PM EDT - 11 months ago

Immunome Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Immunome Slides: Corporate Presentation

Sep 8, 2025, 6:00 PM EDT - 11 months ago

Immunome Slides: Corporate Presentation

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 11 months ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Immunome Quarterly report: Q2 2025

Aug 6, 2025, 9:30 AM EDT - 1 year ago

Immunome Quarterly report: Q2 2025

Immunome Earnings release: Q2 2025

Aug 6, 2025, 9:30 AM EDT - 1 year ago

Immunome Earnings release: Q2 2025

Immunome Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Immunome Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Immunome Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 9:30 AM EDT - 1 year ago

Immunome Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Immunome Slides: Investor Presentation

May 21, 2025, 10:00 AM EDT - 1 year ago

Immunome Slides: Investor Presentation

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Immunome Earnings release: Q1 2025

May 12, 2025, 12:00 AM EDT - 1 year ago

Immunome Earnings release: Q1 2025

Immunome Quarterly report: Q1 2025

May 12, 2025, 12:00 AM EDT - 1 year ago

Immunome Quarterly report: Q1 2025

Immunome Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Immunome Proxy statement: Proxy Filing

Immunome Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Immunome Proxy statement: Proxy Filing

Immunome Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 12:45 PM EDT - 1 year ago

Immunome Transcript: 24th Annual Needham Virtual Healthcare Conference

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Immunome Annual report: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Immunome Annual report: Q4 2024

Immunome Earnings release: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Immunome Earnings release: Q4 2024

Immunome Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Immunome Transcript: Leerink Global Healthcare Conference 2025

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Mar 10, 2025, 7:41 AM EDT - 1 year ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:10 PM EST - 1 year ago

Immunome Transcript: TD Cowen 45th Annual Healthcare Conference

Immunome to Present at Upcoming March Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Immunome to Present at Upcoming March Conferences

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2025, 4:01 PM EST - 1 year ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 29, 2025, 11:11 PM EST - 1 year ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 12:45 PM EST - 1 year ago

Immunome Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Immunome Slides: FY 2025

Jan 15, 2025, 12:45 PM EST - 1 year ago

Immunome Slides: FY 2025

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 4:30 PM EST - 1 year ago

Immunome Transcript: Piper Sandler 36th Annual Healthcare Conference

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immunome Quarterly report: Q3 2024

Immunome Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immunome Earnings release: Q3 2024

Immunome Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 10:30 AM EST - 1 year ago

Immunome Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 7:00 AM EDT - 2 years ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 5:35 PM EDT - 2 years ago

Immunome Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Immunome Quarterly report: Q2 2024

Immunome Earnings release: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Immunome Earnings release: Q2 2024

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 2 years ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome Appoints Phil Tsai as Chief Technical Officer

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024, 8:00 AM EDT - 2 years ago

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 17, 2024, 8:00 AM EDT - 2 years ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 8:00 AM EDT - 2 years ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Immunome Quarterly report: Q1 2024

Immunome Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Immunome Earnings release: Q1 2024

Immunome Slides: Corporate Presentation

May 13, 2024, 7:00 AM EDT - 2 years ago

Immunome Slides: Corporate Presentation

Immunome to Present at 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

May 2, 2024, 8:00 AM EDT - 2 years ago

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Immunome Proxy statement: Proxy Filing

Immunome Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Immunome Proxy statement: Proxy Filing

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 25, 2024, 8:26 AM EDT - 2 years ago

Immunome Appoints Sandra M. Swain to Board of Directors

EZ_Money11
EZ_Money11 Jul. 20 at 11:36 AM
$IMNM 🗞️
0 · Reply
JFais
JFais Jul. 14 at 9:17 PM
$PBLS - strong price action since IPO, marching to new highs (initial data in desmoid looks better than $IMNM and $SWTX + quite a few expansion opportunities on deck) More of this is good for $XBI (vs "science projects" coming to market & blowing up, burning investors like the 2021 bubble)
0 · Reply
Davidendz
Davidendz Jul. 14 at 6:16 PM
$BVAXF Temp halt on $BIOV.CSE $BVAXF = paperwork after nabbing DPX platform in '24. MVP-S data popping, Sona collab, Tartaglia firepower! Platform ready to roll like $IBRX $IMNM.
1 · Reply
Davidendz
Davidendz Jul. 14 at 6:15 PM
$BVAXF Halt on $BIOV.CSE sucks but DPX deal closed 2024, they're building a real platform. Check $IMNM $STOK for similar vibes. Loading when it frees up.
0 · Reply
Davidendz
Davidendz Jul. 14 at 6:15 PM
$BVAXF Frustrating halt on $BIOV $BVAXF but DPX platform fully acquired 2024, smart move for broad applications. Positive trials, Tartaglia hire, partnerships stacking up. Long-term value play like other immuno platforms $IMNM $IMCR. Patient holders win when filings clear!
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 13 at 1:18 PM
Radiopharm Theranostics ($RADX) Jumps as Nuclear-Medicine Interest Builds $LNTH $IMNM $PYXS Source: Kalkine https://kalkine.com.au/news/healthcare/radiopharm-theranostics-asxrad-jumps-as-nuclear-medicine-interest-builds
0 · Reply
FlyontheCEOSwall
FlyontheCEOSwall Jul. 10 at 7:45 PM
$IMNM he can sell it anytime he wants to bears so when he does it will be substantial
0 · Reply
fda_tracker
fda_tracker Jul. 9 at 6:51 PM
$IMNM New PDUFA Date 2027-04-28 IMMUNOME, INC. Link: https://www.businesswire.com/news/home/20260708283482/en/Immunome-Announces-U.S.-FDA-Acceptance-of-New-Drug-Application-for-Varegacestat-for-the-Treatment-of-Adults-with-Desmoid-Tumors Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
Merlintrader
Merlintrader Jul. 9 at 6:00 AM
$IMNM Immunome Deep Dive: Varegacestat Enters FDA Review and Turns $IMNM Into a Cleaner Regulatory-Catalyst Story https://www.merlintrader.com/immunome-imnm-varegacestat-fda-pdufa-2027/
0 · Reply
Jeff9905
Jeff9905 Jul. 8 at 12:15 PM
$IMNM great news. Why is it down?
1 · Reply
FlyontheCEOSwall
FlyontheCEOSwall Jul. 7 at 4:49 PM
$IMNM yes sir
0 · Reply
Doozio
Doozio Jul. 3 at 4:14 PM
$IMNM ENTA 🐒🍌🧠⏰♾️
0 · Reply
KenCowboys
KenCowboys Jul. 2 at 8:22 PM
$IMNM on watchlist. Any reason for the big pop today?
0 · Reply
Jeff9905
Jeff9905 Jun. 25 at 8:56 PM
$IMNM head fake I guess. Still don't get why they can't get any approvals. So much for the Clay effect.
0 · Reply
JoskinCp
JoskinCp Jun. 25 at 3:03 PM
$IMNM Any notice?to 30?
0 · Reply
Jeff9905
Jeff9905 Jun. 25 at 2:12 PM
$IMNM something is up.
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Jun. 16 at 3:21 PM
$IMNM fucking junk
1 · Reply
Jeff9905
Jeff9905 Jun. 15 at 10:26 PM
$IMNM AI is helping multiple biotechs accelerate their products to market. Why not here? Something is off.
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 10 at 11:36 AM
Monday is June 15th. Last time Radiopharm released data on Sunday Dec 15th. And it’s been 2 mos since trial ended. Fingers crossed good news on Sunday. https://m.youtube.com/watch?v=BmpSfQi1SHg&ra=m $RADX $IMNM
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 6 at 5:24 PM
$RADX < $5 - Radiopharm Theranostics 🔹Phase 2b interim showed 90% PET–MRI concordance (18/20) 🔹FDA Fast Track designation granted for RAD101 U.S. supply agreement with Siemens Healthineers for 18F manufacturing 🔹Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer 🔹Low OS near 11M shares $IMNM $INMB $IOVA
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Jun. 4 at 4:24 PM
$IMNM yawn wtf is actually happening here. Just get to 40 already so i can gtfo of this shithole
1 · Reply
HunterT
HunterT Jun. 2 at 5:26 PM
$IMNM Buy zone, 🫡 the floor is $19
0 · Reply